API intermediate market seen reaching $220.78 billion by 2030

By AI, Created 11:36 AM UTC, May 20, 2026, /AGP/ – The global active pharmaceutical ingredient intermediate market is projected to rise from $153.97 billion in 2025 to $165.89 billion in 2026, according to The Business Research Company. The report points to supply chain reshoring, tighter regulation and rising drug demand as key forces behind growth to $220.78 billion by 2030.

Why it matters: - API intermediates are the chemical building blocks used to make active pharmaceutical ingredients, which are essential in medicines. - The market’s growth reflects rising global demand for pharmaceuticals and continued expansion in drug manufacturing. - The forecast suggests more business for manufacturers, contract development and manufacturing organizations, and suppliers of high-purity chemical inputs.

What happened: - The Business Research Company projected the active pharmaceutical ingredient intermediate market will reach $220.78 billion by 2030. - The market is expected to grow from $153.97 billion in 2025 to $165.89 billion in 2026. - The report puts 2026-2030 growth at a 7.4% compound annual growth rate. - The report is titled Active Pharmaceutical Ingredient (API) Intermediate Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The company published the market update from London on May 6, 2026. - A free sample of the report is available. - The full market report is also available.

The details: - Historical growth has been linked to pharmaceutical manufacturing expansion, cost advantages in emerging economies, chemical synthesis expertise, rising generic drug demand and broader healthcare growth. - Future growth drivers include reshoring of pharmaceutical supply chains, higher regulatory scrutiny, advances in synthesis technologies, growth in biotech intermediates and more pharma R&D. - Market trends include greater outsourcing of API intermediate production, more contract development and manufacturing organization partnerships, higher demand for high-purity intermediates, tighter regulatory-compliant manufacturing and expansion in generic drug production. - An API intermediate is a compound formed during the synthesis of an active pharmaceutical ingredient and often requires further processing or purification before use in a medicine. - The report says API intermediates are important for quality and efficiency in pharmaceutical manufacturing. - In April 2024, Eurostat reported medicinal and pharmaceutical product imports into the EU rose 6.1% in 2023 to $129 billion (€119 billion). - Eurostat said EU exports of those products totaled $300 billion (€277 billion), creating a trade surplus of $171 billion (€158 billion). - The report also says North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The regional scope includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast points to a market shaped by both industrial policy and health care demand. - Supply-chain reshoring and regulatory pressure suggest more production may move closer to end markets or into compliance-heavy facilities. - The size of the forecast also signals continued reliance on third-party manufacturers and specialized chemical producers.

What’s next: - Growth in API intermediates will likely track pharmaceutical demand, generic drug production and investment in synthesis technology. - Regional competition should intensify as Asia-Pacific expands faster while North America retains the largest base. - Companies in the sector may lean further into CDMO partnerships and outsourcing to meet purity and compliance expectations. - More information is available in the company’s related market reports on active pharmaceutical ingredients, pharmaceutical chemicals and veterinary active pharmaceutical ingredients manufacturing.